Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers
U.S. STOCKS ON THE MOVE-NervGen Pharma, Medline, Silver miners
U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co
Denali falls after scrapping development of Parkinson's drug
NASDAQ RESUMED AT 06:35 PM
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study (updated)
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
NASDAQ TRADE HALT HALT NEWS PENDING AT 05:55 PM
Biogen climbs on plans to advance development of experimental Alzheimer's therapy
Denali Therapeutics Q1 net loss narrows as expenses fall
Brief: Denali Therapeutics Q1 Operating Expenses USD 137.357 Million
US FDA's accelerated approval for drugs needs more transparency, says research firm (updated)
US FDA's accelerated approval for drugs needs more transparency, says research firm
U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali
Denali slips as Takeda exits dementia drug partnership
Street View: Denali's first FDA nod signals regulatory flexibility for rare disease approvals